Interested in our Q3 financial results?

Oct 24, 2023

Today, Boston Scientific shared its financial results for the third quarter of 2023.

Overall, we generated net sales of $3.527 billion during the third quarter of 2023, growing 10.2 percent on an organic basis[1] compared to the prior year period.

We also achieved net sales growth in each of our reportable segments, with 9.4 percent organic growth in MedSurg and 10.6 percent organic growth in Cardiovascular compared to the prior year period.

“We achieved another quarter of strong performance, thanks to the hard work of our talented global team and our differentiated medical technologies that improve the lives of patients across the globe,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “As we shared at our recent Investor Day meeting, we are well-positioned for the long term, backed by our category leadership strategy, strong pipeline of innovation and track record of strong commercial execution."

Additional highlights:

  • We announced positive 12-month results from the ADVENT pivotal clinical trial demonstrating that the FARAPULSE™ Pulsed Field Ablation (PFA) System[2] is noninferior to current standard-of-care therapies for the treatment of paroxysmal atrial fibrillation (AF).
  • We received U.S. Food and Drug Administration (FDA) approval for the POLARx™ Cryoablation System, which is used to treat of patients with paroxysmal AF.
  • We received FDA approval of the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device, which is designed to reduce device-related thrombus post-implant and treat a broader range of patient anatomies.
  • We received CE Mark, FDA clearance and Japanese Pharmaceuticals and Medical Devices Agency approval for the AVVIGO™+ Multi-Modality Guidance System, which provides high-quality intravascular ultrasound imaging and physiologic assessment of coronary vessels and lesions.
  • We announced an agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the only FDA-cleared system – the Intracept® Intraosseous Nerve Ablation System – for vertebrogenic pain, subject to customary closing conditions.

For the full Boston Scientific earnings announcement and more business highlights from the third quarter of 2023, see the press release.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of health care. For more information, visit and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “may,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance; our business plans and product performance, and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: the impact of foreign currency fluctuations; future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; disruptions caused by pandemics on our operations and financial results; labor shortages and increases in labor costs; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this release.

Use of Non-GAAP Financial Information

This press release contains non-GAAP measures in talking about the company’s performance. The reconciliations of those non-GAAP financial measures to their most comparable GAAP measures is included below.

Net sales for the second quarter by reportable segment









Three Months Ended

September 30,


Reported Basis


Impact of Foreign Currency Fluctuations


Operational Basis


Impact of Recent Acquisitions / Divestitures


Organic Basis

(in millions)










$            629

$            559


12.6  %


(0.7) %


11.9  %


(1.4) %


10.6  %






11.5  %


(0.5) %


11.1  %


—  %


11.1  %






3.7  %


(0.4) %


3.2  %


—  %


3.2  %






10.6 %


(0.5)       %


10.0 %


(0.6)       %


9.4 %






11.4  %


(0.1) %


11.4  %


—  %


11.4  %


   Peripheral Interventions




12.3  %


0.6  %


12.9  %


(4.5) %


8.4  %






11.6 %


0.1 %


11.7 %


(1.1)       %


10.6 %

Net Sales

$       3,527

$       3,170


11.2 %


(0.1)       %


11.1 %


(0.9)       %


10.2 %





















[1] Organic net sales growth is a non- U.S. generally accepted accounting principles (non-GAAP) measure that excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

[2] The FARAPULSE PFA System is an investigational device. Restricted by Federal law to investigational use only. Not available for sale in the U.S.